Best Nucleic Podcasts (2024)

1
Episode 16½ - End-of-season 2 commentary 19:23

38m ago19:23

19:23

Send us a Text Message.By Miłosz Wieczór

1
Episode 16 - Janusz Bujnicki: Structural modeling, RNA modifications, and advising policy-makers on science 28:51

4d ago28:51

28:51

Send us a Text Message. In the sixteenth episode, Janusz Bujnicki tells me about his early switch to bioinformatics, a stroke of serendipity that defined his future career, and how he later managed to reincorporate both biophysics and experimental biology into his research agenda. We talk about the current state of the field of RNA structural predi…

1
Episode 15 - Paulo CT Souza: Developing a universal coarse-grained force field, and approaching the science of molecular complexity 26:41

11d ago26:41

26:41

Send us a Text Message. In the fifteenth episode, Paulo Souza and I discuss the challenges inherent in managing a project of such a scope, and the philosophy behind the systematic way in which Martini is continuously improved and reparameterized. Paulo describes how a user-centric approach helps refine and troubleshoot the model through its widesca…

1
Episode 14 - Syma Khalid: New ways to fight bacteria, the bacterial envelope, and kindness & openness in academia 23:00

29d ago23:00

23:00

Send us a Text Message. In the fourteenth episode, Syma Khalid and I talk about the challenges we're faced with when trying to understand the environment of the bacterial cell envelope, and the outer membrane in particular. We discuss how the lessons taken from the computational study of these structures can inform the design of future antibacteria…

1
Episode 13 - Daniel Zuckerman: Trajectory ensembles, writing books, and learning biology through physics 29:45

26d ago29:45

29:45

Send us a Text Message. In the thirteenth episode, Daniel Zuckerman and I talk about textbooks on statistical biophysics and a physics-based vision of biology, a few of which he himself authored. Daniel reveals that his passion for clarity in writing comes from his early humanities background, and makes a case for how well-thought and physically mo…

1
Episode 12 - Vlad Cojocaru: Simulating transcriptional regulation, returning to our home countries, and the scales of the genome 27:12

1M ago27:12

27:12

Send us a Text Message. In the twelfth episode, Vlad Cojocaru and I discuss how the simulation field can integrate further layers of complexity in modeling transcription control and genome organization in humans. Vlad shares his insights on the computational biology of transcription factors, including DNA-mediated allostery and pioneer transcriptio…

1
Episode 11 - Justin Lemkul: Providing technical help online, sharing expertise, and polarization in nucleic acids 29:38

2M ago29:38

29:38

Send us a Text Message. In the eleventh episode, Justin Lemkul and I talk about the motivations and challenges behind providing technical help on online forums and mailing lists. Justin shares his story of becoming a prolific technical advisor for the Gromacs community, which evolves into a discussion about automatability, the role of expertise in …

1
Episode 10 - Ariane Nunes-Alves: Kinetics in drug design, molecular crowding, and the social life of a PI 19:13

2M ago19:13

19:13

Send us a Text Message. In the tenth episode, Ariane Nunes-Alves and I talk about a kinetics-centric view of drug design, making the case that modeling kinetics in atomistic simulation is an important frontier that, despite clear biomedical relevance, is rarely explicitly addressed either in model parameterization or with the latest AI methods. We …

1
Episode 9 - Michele Vendruscolo: Preventing protein misfolding, fostering public engagement of scientists, and AI tools in drug design 31:21

2M ago31:21

31:21

Send us a Text Message. In the ninth episode, Michele Vendruscolo and I discuss the current state of research on misfolding diseases, typically associated with excessive protein aggregation and formation of insoluble amyloids. Michele presents an optimistic perspective in which the convergence of recent clinical and software developments opens up n…

1
Episode 8½ - My commentary: Wrapping up the first season 20:15

3M ago20:15

20:15

Send us a Text Message. In this episode, I'm attempting to string together the most common threads brought up by my guests in the first eight interviews on the podcast. Reflecting on these conversations, I'm suggesting some grand challenges for the field in the years to come.By Miłosz Wieczór

1
Episode 8 - Rossen Apostolov: Managing scientific collaboration, the biggest project of European biophysics, and seeding schools of thought 27:13

3M ago27:13

27:13

Send us a Text Message. In the eight episode, Rossen Apostolov and I depart from the standard format to talk about the core concepts behind BioExcel, the European Center of Excellence for computational biology. We discuss their main objectives and challenges, from working with code to organizing schools and webinars, talk about the challenges of su…

1
Episode 7 - Aleksei Aksimentiev: Nanobiotechnology, the importance of mentoring, and engineering serendipity 37:38

3M ago37:38

37:38

Send us a Text Message. In the seventh episode, Aleksei Aksimentiev and I delve into the intersection of physics, biology, and nanotechnology, exploring the innovative world of nanopores and biomolecular sequencing. Aleksei shares his journey from particle physics in Ukraine to leading-edge research in the US, and underscores how on the unpredictab…

1
Episode 6 - Giulia Palermo: Reimagining scientific creativity, the RNA revolution, and truly multiscale systems 24:24

4M ago24:24

24:24

Send us a Text Message. In the sixth episode, Giulia Palermo and I discuss the challenges of studying truly multiscale biomolecular systems, such as the CRISPR/Cas9 complex she famously got involved with. While such problems can take us way out of our comfort zones, they also provide us with clear pathways to innovative and transformative science, …

1
Episode 5 - Paul Robustelli: The dissolving barrier between industry and academia, embracing our artistic side, and new models of funding 30:04

4M ago30:04

30:04

Send us a Text Message. In the fifth episode, Paul Robustelli and I discuss how the once very sharp boundary between academia and industry has been becoming increasingly porous, and what implications it will have for future careers in science. Paul shares his experiences and observations about the competing models of funding scientific research, an…

1
Episode 4 - Modesto Orozco: Computations driving experiments, opening simulation data, and integrating knowledge across sources and scales 24:18

4M ago24:18

24:18

Send us a Text Message. In the fourth episode, Modesto Orozco and I talk about the rough path to the predictive power modern computational science has achieved in biology, and the immense possibilities it opens to today's computational biologists working across the scales of space and time. Modesto also reflects on why sharing simulation data is cr…

1
Episode 3 - Wojtek Kopeć: Science as a social endeavor, learning from industry, and the experience of starting a new lab 35:51

4M ago35:51

35:51

Send us a Text Message. In the third episode, Wojtek Kopeć and I discuss the overlooked yet exciting social aspect of scientific collaboration, and what the world of academia could learn from the industry and statisticians to avoid falling behind. Wojtek also shares his personal experience of starting a lab as a new PI, and we reflect on the role o…

1
Episode 2 - Max Bonomi: Interoperability, AI-generated ensembles, and recognizing all contributions to science 24:24

5M ago24:24

24:24

Send us a Text Message. In the second episode, Max Bonomi and I discuss efforts to achieve interoperability and portability in the computational community, and how the AI structural revolution will unfold to bring us realistic molecular ensembles. We then move on to ask how the entire range of contributions to science can be recognized, particularl…

1
Episode 1 - Pilar Cossio: Modeling experimental setups, overpublishing, and maintaining code 27:00

5M ago27:00

27:00

Send us a Text Message. In the first episode, Pilar Cossio and I discuss the radical progress in integrating simulations with experiments, and the excitement about recent progress in modeling cryo-EM tomography data. We share thoughts on the sustainability of our publishing practices, and comment on the challenges of funding the maintenance of scie…

1
Introduction: Do we really need another podcast? 6:39

5M ago6:39

6:39

Send us a Text Message. What is this all about? Does the computational community need a podcast? Along with the first interview, I'm sharing the idea behind PSI, and explaining why the time is ripe for a new marketplace of ideas to drive the changes in how we do science. Everyone is invited, from ambitious undergraduates to seasoned veterans!…

1
Lighting the touch paper for next generation nucleic acid therapies 32:06

1y ago32:06

32:06

In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable heredit…

1
Realizing the patient-friendly future of clinical trials 23:02

2y ago23:02

23:02

In this episode of Conversations in Healthcare, Ergomed founder Dr. Miroslav Reljanović talks to Mike Ward about how the COVID-19 pandemic has nudged clinical trials towards greater efficiency and inclusivity – and what’s needed to make good on this promising trend. Hosted on Acast. See acast.com/privacy for more information.…

1
How Patient Connect addresses unmet needs at the point of care 22:32

2+ y ago22:32

22:32

In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Grace Lomax, Clinical Director at Patient Connect, a part of Clarivate. Grace’s experience as a physician highlighted numerous unmet needs beyond just clinical issues – especially around healthcare literacy, education at the point of care, adherence and more. She discusses ho…

1
Social determinants: barriers to healthcare impacting racial and ethnic minorities 45:59

2+ y ago45:59

45:59

In this episode of Conversations in Healthcare, Matthew Arnold, Principal Analyst at Clarivate speaks with Dr. Kenton Johnston, Associate Professor of Health Management and Policy at Saint Louis University about disparities in the US health system. Matthew and Ken discuss both the historical context as well as the evolution of the system since the …

1
How Novo Ventures prioritized their investment strategy during the pandemic 25:50

2+ y ago25:50

25:50

In this episode of Conversations in Healthcare, Mike Ward speaks with Naveed Saddiqi, Senior Partner at Novo Ventures, one of the largest venture capital groups in the life sciences sector. Naveed shares about the firm’s mandate to generate funds for the Novo Nordisk Foundation, how the pandemic impacted their investment strategy and what excites h…

1
How Healx uses AI to transform rare disease drug discovery 27:52

2+ y ago27:52

27:52

In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Tim Guilliams, the co-founder and CEO of Healx. Healx is an artificial intelligence-powered technology company that's dedicated to helping rare disease patients access life improving treatments. Mike and Tim discuss the company’s innovative approach to drug discovery, choosin…

1
How the pandemic shifted Roche’s priorities and R&D investments 31:20

2+ y ago31:20

31:20

In this episode of Conversations in Healthcare, Mike Ward speaks with Richard Erwin, general manager and managing director of Roche Products Limited (UK), which was recorded in collaboration with One Nucleus's ON Helix conference (June 2021). Richard shares how the pandemic has shifted Roche’s priorities and why the organization has heavily increas…

1
Optimizing patient-first clinical trials with advanced site intelligence 40:56

2+ y ago40:56

40:56

In this episode of Conversations in Healthcare, Mike Ward speaks with Oriol Serra, former Head of Site Intelligence and Selection at Pfizer and Simon Andrews, Vice President of RWD Engagements and Innovations at Clarivate about optimizing patient-first clinical trial design and ensuring trial groups align to real-life populations and needs. The gro…

1
Showing the value of regulatory intelligence in pharma 31:32

3y ago31:32

31:32

In this episode of Conversations in Healthcare, Mike Ward speaks with Carolyn Hynes, Director of Regulatory Intelligence at AstraZeneca, and Céline Rodier, Senior Health Policy Manager at Clarivate, about strategies and tools to gather and assess regulatory intelligence, as well as KPIs and approaches to demonstrating ROI within your organization. …

1
Overcoming health inequity in the U.S. and the role of telehealth: Ideas and best practices from Cigna, Henry Ford Health System and the eHealth Initiative 36:46

3y ago36:46

36:46

Increased reliance on telehealth services has been one of the most significant care delivery shifts prompted by the COVID-19 pandemic. However, the pandemic has also thrown more light on the challenges of health inequity in the United States, especially among African American and Hispanic communities. We discuss these issues and potential solutions…

1
Best practices for university - healthcare partnerships: Learnings from the Institute of Cancer Research 27:59

3y ago27:59

27:59

In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Toby Richardson, who is Head of Business Development and Licensing; Deputy Director of Business and Innovation at The Institute of Cancer Research. Mike and Toby discuss how research collaborations betwee…

1
Best practices for university – healthcare partnerships: Learnings from Oxford 35:15

3y ago35:15

35:15

In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Dr. Phil Clare, the Deputy Director, Research Services (Knowledge Exchange and Engagement) at the University of Oxford. Mike and Dr. Clare discuss the key role that university research plays in shaping new me…

1
The evolution of the asset-centric approach in biotech venture capital 47:29

3y ago47:29

47:29

In this episode of Conversations in Healthcare, Mike Ward, Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, speaks with Francesco De Rubertis, a co-founder and managing partner at Medicxi, one of the most prominent financial supporters of innovative biotech activity. Francesco provides insights into how the biotech venture cap…

1
Drugs to Watch 2021 23:50

3y ago23:50

23:50

Clarivate market experts break down the opportunities and potential threats for 2021’s Drugs to Watch – the key drugs expected to be blockbusters by 2026. Hosted on Acast. See acast.com/privacy for more information.

1
How Glympse Bio oversubscribed their Series B funding amidst the pandemic 44:12

3+ y ago44:12

44:12

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Caroline Loew, President and CEO from Glympse Bio. They discuss the biotech’s focus on both disease detection and response to treatment using bioengineered sensors, starting with NASH. Dr. Loew also shares career a…

1
The past, present and future of next generation sequencing 30:07

3+ y ago30:07

30:07

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Nick McCooke, CEO of Longas Technologies. Having been at the forefront of developing next generation sequencing, Nick talks to Mike about his past work, current projects and future predictions for this key technology in …

1
COVID-19, multi-stem clinical trials and a new way of fundraising 50:05

3+ y ago50:05

50:05

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Gil Van Bokkelen, founder, chairman and CEO of Athersys Inc. They discuss the company’s clinical program that is focusing on a special class of stem cells which display very unique properties and have been obtained from healthy young consenting don…

1
Early planning key to successful access and product launch 29:35

3+ y ago29:35

29:35

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, speaks with Alison Kneen, Senior Vice President, Global Market Access and Head of the Centre of Innovation and Regulatory Science (CIRS) and DRG Abacus. Learn why early and thorough planning is so important for a successful product launch, and how A…

1
Transforming the treatment of cancer with oncolytic viruses 33:06

3+ y ago33:06

33:06

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, speaks with Stephen Russell, CEO of Vyriad. Dr. Russell reveals invaluable insights for those looking for or currently putting together partnership deals. Stephen shares his journey from academia at the Mayo Clinic to founding Vyriad, and eventually…

1
Possible treatment for COVID-19 related respiratory failure 21:37

3+ y ago21:37

21:37

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Jonathan Javitt, CEO of NeuroRx. Dr Javitt discusses how NeuroRx is working in collaboration with Relief Therapeutics on Aviptadil, a synthetic version of vasoactive intestinal peptide, and a potential treatment of COV…

1
Pivoting a product launch during the pandemic 35:23

3+ y ago35:23

35:23

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, h…

1
Utilizing pluripotent stem cells in cell therapy 25:55

3+ y ago25:55

25:55

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Brian Culley, CEO of Lineage Cell Therapeutics. Brian and Mike discuss the company’s cell therapy program, utilizing pluripotent stem cells, initially targeting dry age-related macular degeneration, acute spinal cord i…

1
A novel approach to treating neurodegenerative disease 26:19

3+ y ago26:19

26:19

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Leen Kawas, president and CEO of Athira Pharma. Dr. Kawas shares the company’s innovative approach to treating Alzheimer’s disease by developing small molecules to restore neuronal health and stop neurodegeneration…

1
An update from biopharma’s hotspot 27:26

3+ y ago27:26

27:26

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, Part of Clarivate talks to Bob Coughlin, president and CEO of the Massachusetts Biotechnology Council. Bob provides insights from what is unarguably the world’s number one biopharma hotspot. Bob and Mike discuss how the industry…

1
Collaborating with officials to continue developments 39:08

3+ y ago39:08

39:08

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Joe Panetta, President and CEO of BIOCOM. Joe talks around how BIOCOM has worked closely with government officials to ensure the life science community can continue to function throughout the COVID-19 pandemic, and how t…

1
How including patients can help with the fight against Parkinson’s Disease 21:27

3+ y ago21:27

21:27

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Charlotte Allen and Russ Bradford from Parkinson’s Concierge. Russ and Charlotte offer a unique insight into how being a patient centric organisation enables them to help the Parkinson’s Disease community improve their q…

1
Maximising R+D efforts through better epidemiology understanding 23:13

3+ y ago23:13

23:13

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Mike Hughes, Senior Director of Epidemiology at DRG. With epidemiology entering our daily vernacular, thanks to the Covid-19 pandemic, Mike gives a definition of what it is, the approaches used to model epidemiology ass…

1
Addressing strategic challenges for biotech companies 30:55

3+ y ago30:55

30:55

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at DRG Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology comp…

1
Bringing together minds to combat COVID-19 27:01

3+ y ago27:01

27:01

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Sir Mene Pangalos, Executive Vice President at AstraZeneca. Sir Mene talks to Mike about AstraZeneca's learnings from helping Chinese colleagues combat Coronavirus at the end of 2019, and then expanding input as it becam…

1
An unprecedented time of scientific innovation 39:27

3+ y ago39:27

39:27

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Houman Ashrafian, Managing Partner at SV Health Investors. Houman gives an interesting perspective into how and why biotech investment has remained robust throughout the Covid-19 pandemic. He talks to Mike about his pro…

1
Securing investments amidst COVID-19 and Brexit uncertainties 33:57

3+ y ago33:57

33:57

In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Hakan Goker, Vice President of M Ventures. Hakan gives a unique insight into how both COVID-19 and Brexit are affecting current investment opportunities for both investors and start-ups, including restrictions on travel,…

Podcasts Worth a Listen

Nucleic Podcasts

Podcasts Worth a Listen

Quick Reference Guide